Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by NAOTO T UENO and CHANDRA BARTHOLOMEUSZ.
NAOTO T UENO
Connection Strength
5.829
CHANDRA BARTHOLOMEUSZ
  1. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Mol Cancer Ther. 2015 Dec; 14(12):2773-81.
    View in: PubMed
    Score: 0.529
  2. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther. 2012 Feb; 11(2):360-9.
    View in: PubMed
    Score: 0.407
  3. Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. J Cancer. 2011; 2:435-42.
    View in: PubMed
    Score: 0.398
  4. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res. 2010 Mar 15; 16(6):1802-11.
    View in: PubMed
    Score: 0.361
  5. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res. 2008 Nov 15; 68(22):9302-10.
    View in: PubMed
    Score: 0.329
  6. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene. 2006 Jan 05; 25(1):79-90.
    View in: PubMed
    Score: 0.270
  7. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res. 2005 Sep 15; 65(18):8406-13.
    View in: PubMed
    Score: 0.264
  8. Correction: Maternal Embryonic Leucine Zipper Kinase Is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Res Commun. 2024 Jan 29; 4(1):236.
    View in: PubMed
    Score: 0.236
  9. Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Res Commun. 2023 06; 3(6):1078-1092.
    View in: PubMed
    Score: 0.226
  10. Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. Breast Cancer Res Treat. 2021 Sep; 189(2):333-345.
    View in: PubMed
    Score: 0.198
  11. Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. Mol Cancer Ther. 2021 02; 20(2):296-306.
    View in: PubMed
    Score: 0.190
  12. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Sci Rep. 2020 05 22; 10(1):8537.
    View in: PubMed
    Score: 0.183
  13. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jul; 176(1):251.
    View in: PubMed
    Score: 0.172
  14. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(2):339-351.
    View in: PubMed
    Score: 0.168
  15. EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget. 2017 Sep 15; 8(40):67904-67917.
    View in: PubMed
    Score: 0.150
  16. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. Oncogene. 2017 05 04; 36(18):2599-2608.
    View in: PubMed
    Score: 0.144
  17. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther. 2015 Dec; 14(12):2687-99.
    View in: PubMed
    Score: 0.133
  18. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat. 2014 Jul; 146(2):259-72.
    View in: PubMed
    Score: 0.121
  19. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol Cancer Ther. 2013 Jun; 12(6):1099-111.
    View in: PubMed
    Score: 0.111
  20. Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells. Oncogene. 2014 Jan 23; 33(4):440-8.
    View in: PubMed
    Score: 0.110
  21. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):331-45.
    View in: PubMed
    Score: 0.108
  22. PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking ?-catenin. Oncogenesis. 2012 Jul 16; 1:e22.
    View in: PubMed
    Score: 0.106
  23. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist. 2011; 16(7):956-65.
    View in: PubMed
    Score: 0.099
  24. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011 Sep; 122(3):641-7.
    View in: PubMed
    Score: 0.098
  25. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther. 2008 Jul; 7(7):1846-50.
    View in: PubMed
    Score: 0.080
  26. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther. 2007 Aug; 6(8):2168-77.
    View in: PubMed
    Score: 0.075
  27. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 2007 Jun 15; 67(12):5779-88.
    View in: PubMed
    Score: 0.075
  28. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol Cancer Ther. 2007 Jan; 6(1):227-35.
    View in: PubMed
    Score: 0.072
  29. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res. 2007; 9(4):R41.
    View in: PubMed
    Score: 0.072
  30. Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells. Cancer Gene Ther. 2006 May; 13(5):451-9.
    View in: PubMed
    Score: 0.069
  31. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res. 2002 Nov 15; 62(22):6712-6.
    View in: PubMed
    Score: 0.054
  32. Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. Cells. 2020 02 24; 9(2).
    View in: PubMed
    Score: 0.045
  33. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9.
    View in: PubMed
    Score: 0.045
  34. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer. 2015; 6(12):1306-19.
    View in: PubMed
    Score: 0.033
  35. Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett. 2015 Jan 28; 356(2 Pt B):374-381.
    View in: PubMed
    Score: 0.031
  36. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500.
    View in: PubMed
    Score: 0.030
  37. Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol. 2010 Dec; 100(3):449-57.
    View in: PubMed
    Score: 0.023
  38. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.